De Novo device
iTEAR Neurostimulator
Olympic Ophthalmics, Inc. · Electromechanical Tear Stimulator (QKV, Class II) · First FDA decision May 1, 2020, newest May 1, 2020Dry eye
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
2
Naming "iTEAR"
MAUDE reports
0
Brand "iTEAR", since 2015
PubMed studies
3
Mentioning "iTEAR"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing iTEAR Neurostimulator
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- iTEAR NeurostimulatorNew device typeDe Novo
DEN190026 · Decided May 1, 2020 · 352 days after receipt
Device type: Electromechanical Tear Stimulator (QKV) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "iTEAR", any status and sponsor, newest update first.
- iTear Single-center, Open-label, Single-arm StudyStatus unknown
The University of Hong KongAcademic, hospital or other
NCT06525961 · 30 participants (planned) · Start Aug 2024 · Primary completion Aug 2025
Device: iTEAR100 Neurostimulator · For: Dry Eye Disease; Dry Eye Syndromes; Dry Eye and 1 more
Sites: Hong Kong, Hong Kong
- Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal UsersStatus unknown
Olympic Ophthalmics, Inc.Not on our public-company list
NCT04763018 · 35 participants (planned) · Start Feb 17, 2021 · Primary completion May 1, 2021
Device: iTEAR100 · For: Visual Display Users With Previously Undiagnosed Dry Eye
Sites: Palo Alto, California
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "iTEAR", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QKV
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "iTEAR"[tiab]. The summary above synthesizes these.
- Novel Extranasal Tear Stimulation: Pivotal Study Results.
Ji MH, Moshfeghi DM, Periman L, et al. · Transl Vis Sci Technol · 2020Clinical Trial, Multicenter Study
- Surge in Eye Drop Safety Concerns and Interest in Alternative Dry Eye Disease Therapy Following Eye Drop Recalls: A Cross-Sectional Google Trends Analysis.
Martinyan J, Starr CE · Eye Contact Lens · 2025
- Application of OSA-VET® and qualiquantitative tear tests in brachycephalic dogs with and without keratoconjunctivitis sicca.
Voitena JN, Brito FLC, Marinho TOC, et al. · Vet Res Commun · 2024
Other devices of this type
Also filed under product code QKV.
- iTEAR100 NeurostimulatorOlympic Ophthalmics · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.